Management of Influenza‑Associated Benign Acute Childhood Myositis (BACM)

Diagnosis and Initial Testing

• Perform rapid influenza testing using nasopharyngeal aspirate or nose/throat swabs to confirm infection in children with flu‑like illness and calf pain. 1, 2

Antiviral Therapy

• Initiate oseltamivir within 48 hours of symptom onset in any child with high clinical suspicion for influenza, without waiting for test results. 3, 1
• Dosage – Weight‑based regimen:
  
  • 15–23 kg (typical age 3–7 years): 45 mg every 12 hours. 4
  • ≥24 kg: 75 mg every 12 hours. 5
• Duration – Treat for a total of 5 days. 2
• Early initiation of oseltamivir improves outcomes and reduces complications; therefore, therapy should not be delayed while awaiting diagnostic results. 6, 7
• The British Infection Society and British Thoracic Society give a strong recommendation for oseltamivir as the antiviral of choice in children, citing reduction in secondary bacterial infections. 3, 5

Antibiotic Considerations

• Add co‑amoxiclav when there are clinical signs of secondary bacterial infection or severe illness. 1, 4
• Indications for antibiotics include:
  
  • Radiographic or clinical evidence of pneumonia (respiratory distress, hypoxia, abnormal chest examination). 1, 2
  • Persistent high fever beyond the expected viral course. 2
  • Any clinical deterioration. 2
• For patients < 12 years, co‑amoxiclav is preferred because it covers the most common post‑influenza bacterial pathogens (Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae). 1, 4, 2

Hospitalization Red‑Flag Criteria

• Admit if any of the following are present:
  
  • Oxygen saturation ≤ 92 % on room air. 2
  • Inability to maintain adequate oral intake. 2
  • Severe respiratory distress. 2
  • Altered mental status. 2
  • Vomiting that may compromise oseltamivir tolerance (vomiting occurs in ≈ 15 % of children receiving the drug). 3, 6

Outpatient Management Eligibility

• Consider outpatient care when:
  
  • No respiratory distress or hypoxia is evident. 2
  • The child can ambulate with assistance. 8
  • Reliable daily follow‑up for CK monitoring is available.

Practical Treatment Considerations

• Do not withhold oseltamivir solely on the basis of a negative rapid antigen test; these tests have low sensitivity (approximately 10–80 %). 6, 7

All facts are derived from peer‑reviewed sources and guideline statements; where a strength of recommendation is provided (e.g., British Infection Society/British Thoracic Society), it is interpreted as a strong recommendation.

Management of Influenza‑Associated Muscle Pain in Children

Clinical Presentation

• Simple viral myalgia in pediatric influenza presents as generalized muscle aches during the acute phase of illness. 9

Analgesic Recommendations

• Acetaminophen (paracetamol) is the preferred analgesic for pain and fever control in children with influenza‑related muscle pain. 9
• Aspirin is absolutely contraindicated in children with influenza because of the risk of Reye’s syndrome. 10

Hydration and Supportive Care

• Aggressive oral hydration is the cornerstone of therapy to prevent progression to rhabdomyolysis; when oral intake is insufficient, enteral supplementation is preferred, and intravenous fluids should be administered at approximately 80 % of basal maintenance rates. 11

Hospitalization Red‑Flag Criteria

• Admit a child if any of the following are present:

Antiviral Therapy (Oseltamivir)

• Initiate oseltamivir within 48 hours of symptom onset when there is high clinical suspicion for influenza. 12
• Recommended weight‑based dosing: 45 mg every 12 hours for children weighing 15–23 kg; 75 mg every 12 hours for children ≥ 24 kg, for a total of 5 days. 12
• Early oseltamivir therapy reduces the incidence of secondary bacterial infections and may shorten overall symptom duration. 9
• Approximately 15 % of treated children experience vomiting, which can compromise medication tolerance. 9

Antibiotic Considerations

• Routine antibiotics are not indicated for uncomplicated viral myositis or myalgia. 11
• If a secondary bacterial infection develops (e.g., clinical or radiographic pneumonia, persistent high fever, clinical deterioration), co‑amoxiclav is the first‑line antibiotic for children < 12 years; clarithromycin or cefuroxime are alternatives for penicillin‑allergic patients. 12

Monitoring & Safety

• Daily monitoring of creatine kinase (CK) levels is advised in children with severe calf pain to ensure down‑trending values and to rule out progression to rhabdomyolysis. 11

All statements are supported by the cited references; the strength of evidence was not explicitly graded in the source material.